Slovenija - slovenski - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - klaritromicin - tableta s prirejenim sproščanjem - klaritromicin 500 mg / 1 tableta - klaritromicin

Slovenija - slovenski - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - klaritromicin - zrnca za peroralno suspenzijo - klaritromicin 25 mg / 1 ml - klaritromicin

Slovenija - slovenski - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - klaritromicin - filmsko obložena tableta - klaritromicin 500 mg / 1 tableta - klaritromicin

Slovenija - slovenski - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - klaritromicin - zrnca za peroralno suspenzijo - klaritromicin 50 mg / 1 ml - klaritromicin

Europska Unija - slovenski - EMA (European Medicines Agency)

abbvie ltd - dasabuvir natrij - hepatitis c, kronični - antivirusi za sistemsko uporabo - zdravilo exviera je indicirano v kombinaciji z drugimi zdravili za zdravljenje kroničnega hepatitisa c (chc) pri odraslih. za virus hepatitisa c (hcv) genotip določene dejavnosti,.

Europska Unija - slovenski - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Europska Unija - slovenski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - rilpivirin hidroklorid - okužbe z virusom hiv - antivirusi za sistemsko uporabo - edurant, v kombinaciji z drugimi protiretrovirusna zdravila, je indicirano za zdravljenje virusom človeške imunske pomanjkljivosti tipa 1 (hiv‑1) okužbe pri bolnikih treatment‑naïve protiretrovirusno 12 let in starejši z virusno obremenitvijo ≤ 100.000 hiv‑1 rna kopij/ml. kot z drugimi protiretrovirusnimi zdravili, genotipa odpornost testiranje mora vodnik za uporabo edurant.

Europska Unija - slovenski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 in 5.

Europska Unija - slovenski - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karcinom, pljučni pljuč - druga zdravila z delovanjem na novotvorbe agenti, protein kinaza inhibitorji - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Europska Unija - slovenski - EMA (European Medicines Agency)

merck sharp & dohme b.v. - elbasvir, grazoprevir - hepatitis c, kronični - direct acting antivirals, antivirals for systemic use, antivirals for treatment of hcv infections - zepatier is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip-specifična aktivnost glej točki 4. 4 in 5.